FOXO Technologies Expects Class A Common Stock to Resume Trading, Today, November 7, in Connection with 1-for-10 Reverse Stock Split
- None.
- None.
The Company’s Common Stock will continue to trade on NYSE American under the symbol "FOXO" and will begin trading on a split-adjusted basis when the market opens today, November 7, 2023.
Mark White, Interim CEO of FOXO Technologies, stated, “In the short time since I took the helm at FOXO, we have undertaken a restructuring of the Company intended to rapidly and cost-effectively drive commercialization of our technology through a new direct-to-consumer offering, as announced last week. The new product offering, designed to maximize value for our stockholders, leverages our epigenetic data and analytics through a commercial partnership with KR8.ai. We are delighted to announce that trading is expected to resume on the NYSE American following the reverse split, and we look forward to announcing a number of key strategic developments on our overall strategy in the days and weeks ahead.”
About FOXO Technologies Inc. (“FOXO”)
FOXO, a technology platform company, is a leader in epigenetic biomarker discovery and commercialization focused on commercializing longevity science through products and services that serve multiple industries. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. For more information about FOXO, visit www.foxotechnologies.com. For investor information and updates, visit https://foxotechnologies.com/investors/.
Forward-Looking Statements
This press release contains certain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein, including statements as to future results of operations and financial position, planned products and services, business strategy and plans, objectives of management for future operations of FOXO, market size and growth opportunities, competitive position, and technological and market trends, are forward-looking statements. Such forward-looking statements include, but not limited to, expectations, hopes, beliefs, intentions, plans, prospects, financial results or strategies regarding FOXO; the future financial condition and performance of FOXO and the products and markets and expected future performance and market opportunities of FOXO. These forward-looking statements generally are identified by the words “anticipate,” “believe,” “could,” “expect,” “estimate,” “future,” “intend,” “strategy,” “may,” “might,” “strategy,” “opportunity,” “plan,” project,” “possible,” “potential,” “project,” “predict,” “scales,” “representative of,” “valuation,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the ability to obtain financing; (ii) the Common Stock resuming trading on NYSE American; (iii) the acceleration of the Company’s outstanding indebtedness evidenced by the
View source version on businesswire.com: https://www.businesswire.com/news/home/20231107427345/en/
Crescendo Communications, LLC
(212) 671-1020
foxo@crescendo-ir.com
Source: FOXO Technologies Inc.
FAQ
What is the reason for FOXO Technologies' stock resuming trading?
What strategic developments is FOXO Technologies planning to announce?